MX2013013574A - Composicion farmaceutica que comprende drotaverina. - Google Patents

Composicion farmaceutica que comprende drotaverina.

Info

Publication number
MX2013013574A
MX2013013574A MX2013013574A MX2013013574A MX2013013574A MX 2013013574 A MX2013013574 A MX 2013013574A MX 2013013574 A MX2013013574 A MX 2013013574A MX 2013013574 A MX2013013574 A MX 2013013574A MX 2013013574 A MX2013013574 A MX 2013013574A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
drotaverine
composition
preparation
relates
Prior art date
Application number
MX2013013574A
Other languages
English (en)
Other versions
MX354485B (es
Inventor
Sudhakara Rao Badabhagni
Nilesh Jaiswal
Praveen Khullar
Kum Prasad
Original Assignee
Chinoin Private Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Private Co Ltd filed Critical Chinoin Private Co Ltd
Publication of MX2013013574A publication Critical patent/MX2013013574A/es
Publication of MX354485B publication Critical patent/MX354485B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención se refiere a una composición farmacéutica de hidrocloruro de drotaverina en un sistema de disolvente adecuada como una composición líquida de relleno. En otro aspecto, la invención también se refiere a un proceso para la preparación de dicha composición farmacéutica y al uso de dicha composición para la preparación de un producto farmacéutico para tratar espasmos y dolores agudos.
MX2013013574A 2011-05-20 2012-05-16 Composición farmacéutica que comprende drotaverina. MX354485B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1728CH2011 2011-05-20
US201161499850P 2011-06-22 2011-06-22
EP11305922 2011-07-13
PCT/EP2012/059163 WO2012159964A1 (en) 2011-05-20 2012-05-16 Pharmaceutical composition comprising drotaverine

Publications (2)

Publication Number Publication Date
MX2013013574A true MX2013013574A (es) 2014-09-22
MX354485B MX354485B (es) 2018-03-07

Family

ID=47216628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013574A MX354485B (es) 2011-05-20 2012-05-16 Composición farmacéutica que comprende drotaverina.

Country Status (10)

Country Link
US (1) US20140080864A1 (es)
EP (1) EP2709599B1 (es)
AR (1) AR086448A1 (es)
BR (1) BR112013029621A2 (es)
EA (1) EA022944B1 (es)
HU (1) HUE038538T2 (es)
MX (1) MX354485B (es)
PL (1) PL2709599T3 (es)
UY (1) UY34081A (es)
WO (1) WO2012159964A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279346A (zh) 2020-03-09 2022-11-01 苏什玛·保罗·伯利亚 包含屈他维林或其盐的控制释放制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197207B (en) * 1985-12-04 1989-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical comprising 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydro-isoquinolinium-theophylline-7-acetate or its monohydrate as active ingredient
HUT60926A (en) * 1991-04-12 1992-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition suitable for reducing or preventing increased thrombocyte-aggregation capability
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents

Also Published As

Publication number Publication date
EA022944B1 (ru) 2016-03-31
WO2012159964A1 (en) 2012-11-29
EA201391743A1 (ru) 2014-03-31
MX354485B (es) 2018-03-07
US20140080864A1 (en) 2014-03-20
BR112013029621A2 (pt) 2016-12-13
EP2709599A1 (en) 2014-03-26
EP2709599B1 (en) 2017-12-20
AR086448A1 (es) 2013-12-11
HUE038538T2 (hu) 2018-10-29
PL2709599T3 (pl) 2018-07-31
UY34081A (es) 2013-01-03

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
AP3438A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
GB201118656D0 (en) New compounds
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MX349004B (es) Nuevos compuestos.
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
HUE054621T2 (hu) Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik
SG11201504791VA (en) Pharmaceutical composition for treating headache, and preparation method thereof
HK1197414A1 (zh) 雌甾- -四烯- -甲酰胺衍生物、其製備方法、包含其的藥物製劑及其用於製備藥物的用途
MX2014000829A (es) Particulas que comprenden un principio activo a base de poliacrilato.
CL2015001020A1 (es) Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica
MX359670B (es) Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
IL235190A0 (en) Liposomes containing oligopeptide fragments of myelin basic protein, medical preparation and method for treating multiple sclerosis
EA201391742A1 (ru) Фармацевтическая композиция, включающая фексофенадин
MX2013013574A (es) Composicion farmaceutica que comprende drotaverina.
EP2612656A4 (en) PROCESS FOR PRODUCING A BLOCKED MEDICAMENT-COPOLYMER COMPOSITE AND PHARMACEUTICAL PRODUCT CONTAINING SAID COMPOSITE
TN2013000470A1 (en) Pharmaceutical composition comprising fexofenadine
UA74882U (uk) Фармацевтична композиція для лікування сексуальної дисфункції
MY169648A (en) Process for preparing products comprising stabilised actives and compositions comprising same

Legal Events

Date Code Title Description
FG Grant or registration